Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy — Frank-D. Goebel (2001) | RDL Network
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy
Article 2001 en
Authors
FG
Frank-D. Goebel
RH
R Hemmer
JS
Jean-Claude Schmit
Abstract
1 min read
The maximal tolerated dosage of ADA appears to be 2 g (three times daily). This study provides safety results that will allow larger clinical trials to confirm the preliminary efficacy data.
Daniel Shao-Weng Tan, Herlinde Dumez, David Olmos, Shahneen Sandhu, Ann Hoeben, Andrew Stephens, Srinivasu Poondru, Richard Gedrich, S.B. Kaye, Patrick Schöffski
John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Nicole Meade, V. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay
Kathryn Maitland, Mainga Hamaluba, Nchafatso G. Obonyo, Emmanuel Oguda, Christabel Mogoka, Thomas N. Williams, Mike Chaponda, Sam Miti, Luc Kambale Kamavu, Roisin Connon, Diana M. Gibb, Arjen M. Dondorp, Nicholas Day, Sir Nicholas White, A. Sarah Walker, Elizabeth C. George
Kathryn Maitland, Mainga Hamaluba, Nchafatso G. Obonyo, Emmanuel Oguda, Christabel Mogoka, Thomas N. Williams, Mike Chaponda, Sam Miti, Luc Kambale Kamavu, Jonathan Gwasupika, Roisin Connon, Diana M. Gibb, Arjen M. Dondorp, Nicholas Day, Sir Nicholas White, Timothy M. Walker, Elizabeth C. George
Discussion(0)
No comments yet. Be the first to comment.